Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe, Daiichi Sankyo Expand Tie-Up to Push DPP-4/SGLT-2 Combo
March 30, 2017
- German Authority Confirms Additional Benefit of Lenvatinib in RCC
March 29, 2017
- Mochida Gets Japan Distribution Rights to Tyvaso
March 29, 2017
- Shionogi Seeks to Expand Pediatric Use for Allergen Immunotherapy Actair
March 29, 2017
- Astellas Unloading 16 Off-Patent Brands to LTL Pharma
March 29, 2017
- Mitsubishi Tanabe to Pull Plug on Generics, Transfer Biz to Nipro in October
March 29, 2017
- Ono Clinches Immuno-Oncology Drug Discovery Deal with Numab
March 29, 2017
- AZ Japan to Introduce Business Unit Structure in April
March 28, 2017
- Tivantinib Fails Japan PIII Trial for HCC: Kyowa Kirin
March 28, 2017
- Nippon Shinyaku Gets Exclusive Japan Rights to Novel AML Drug
March 27, 2017
- Chugai Notches Supreme Court Victory in Oxarol Patent Suit
March 27, 2017
- AZ Gets Asian Rights to Kyowa Kirin’s Benralizumab
March 27, 2017
- Nobelpharma to Copromote Nobelzin with ASKA, Medipal upon Hypozincemia Nod
March 27, 2017
- EMA Accepts Schizophrenia Med Brexpiprazole for Review: Otsuka/Lundbeck
March 27, 2017
- Torii Seeks Pediatric Indication for Allergen Immunotherapy Miticure
March 27, 2017
- Shionogi Gets FDA Nod for Naldemedine
March 27, 2017
- Hit Compounds Enter POC Evaluation Stage in DNDi’s NTD Drug Discovery Booster Project
March 27, 2017
- Alexion Files Soliris for Refractory gMG
March 24, 2017
- Takata, Meiji Settle Patent Suit with Toyama Chemical over Pediatric Ozex Drug
March 24, 2017
- Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain
March 24, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…